The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
复制标题
DOI：
10.1016/j.jneuroim.2020.577323
复制
发表时间：
2020-09-15
影响因子：
3.3
通讯作者：
Mastroianni, Claudio Maria
中科院分区：
文献类型：
--
作者：
Ciardi, Maria Rosa;Zingaropoli, Maria Antonella;Mastroianni, Claudio Maria
1例特氟米特治疗的多发性硬化症合并新冠肺炎肺炎患者入院治疗，15天后康复。分别于感染前1个月和新冠肺炎肺炎期间2个时间点进行外周血细胞免疫表型分析。在感染时点，与感染前相比，CD4+和CD8+T细胞的免疫激活百分率和免疫衰老百分率均无明显差异。我们的评估似乎证实了特氟米特控制T细胞的免疫激活和免疫衰老，这表明特氟米特不应该在新冠肺炎肺炎活动期的MS患者中停用。
A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4 + and CD8 + T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.